

Advantagene to present at Investor Conference

AUBURNDALE, MA (March 4, 2016) - Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that Dr. Estuardo Aguilar-Cordova, Chairman and Chief Executive Officer, will present at the 28th Annual Roth Conference on March 15, 2016, at 8:00 a.m. PCT, at the Ritz Carlton, Dana Point, CA.

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) technology for the treatment of solid tumors. GMCI™ is an “off the shelf” low toxicity immunotherapy that stimulates a patient’s own immune system to generate a robust response against his or her cancer, causing tumor cell death and clearance. Advantagene is conducting a registration clinical trial with its lead clinical candidate, ProstAtak®, for the treatment of newly diagnosed prostate cancer patients under a Special Protocol Assessment issued by the U.S. Food and Drug Administration. If approved, ProstAtak® will be the first and only pharmaceutical intervention available for these patients. The company is conducting additional clinical studies using GMCI™ to treat lung, pancreas and brain cancer with impressive clinical results to date. For more information about Advantagene and our GMCI™ cancer immunotherapy program please visit www.advantagene.com.

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advantagene’s plans and ability to develop its GMCI™ technology to safely and effectively treat cancer. These forward-looking statements are subject to a number of risks. Advantagene undertakes no obligation to update these forward looking statement and you are cautioned not to place undue reliance on any of these forward looking statements. For more information about our company, please visit www.advantagene.com or send an email to info@advantagene.com.